PRISM BioLab is a biotechnology company that specializes in drug discovery using its proprietary PepMetics® Technology to create peptides that mimic α-helix or β-turn structures.

Takehara Dai

PRISM BioLab

大原薬品工業は日本の製薬会社で、医薬品の研究開発、製造、販売を行っている。

大原薬品工業

PRISM BioLab is committed to maximizing the potential of its PepMetics™ Technology, transforming the “undruggable” to “druggable” with the aim of finding cures for the incurable.

PRISM BioLab is a biotechnology company with PepMetics Technology, a proprietary drug discovery platform. PepMetics Molecules are designed to mimic α-helix or β-turn peptides using unique, stable scaffolds.

PRISM BioLab Co., Ltd.

PRISM BioLab BLOG Update! (2023/1/20)

Technology integration: From Cyclic Peptides to Small Molecules

Novel technologies and strategies bring up beautiful sprouts of innovation. In our recent paper1, a two-step strategy for designing a small molecule was demonstrated by collaboration with GeneFrontier through the integration of respective technologies. This is a fantastic example of synergy creation, leveraging each strength to develop a new and practical strategy.

More...

https://lnkd.in/dRBGHvjV

PRISM BioLab BLOG Update! (2022/12/20)

"Targeting PPI: What’s PPI inhibitor?"

PPI-targeted drug discovery strategy is intriguing field. Target identification and functional modulation are crucial for new drug discovery and development. Assay development, technological improvements of structural biology and bioinformatics allowed us to rapidly identify the target so far, even though there are still challenges. Target-based drug discovery is a current standard, and a project often starts with obvious target protein or other biomolecules. It is one of our goals to establish a clearcut strategy and methodology for PPI-targeted drug discovery.

More...
https://lnkd.in/gn78AR_J
#drugdiscovery  #ppi #prismbiolab

PRISM BioLab BLOG Update! (2022/12/16)

"What’s PPI? Introduction to Protein-Protein Interaction"

PRISM is open to all levels of scientific discussion. Our scientists would love to speak with you!

https://lnkd.in/ga7t5AYB

#drugdiscovery #ppi #prismbiolab

PRISM BioLab BLOG Update! (2022/11/16)

Cyclic peptides: Not Just A Goldmine for PPI Drug Discovery

PRISM is open to all levels of scientific discussion. Our scientists would love to speak with you! 

https://lnkd.in/g8dSzHXn

#drugdiscovery #ppi #prismbiolab

【Webinerのお知らせ】Followed by English translation

ファーマインテリジェンス・アワード・ジャパン2022受賞記念ウェビナー『低分子によるPPI阻害：新たな創薬パラダイム』のお知らせ

PRISM BioLabの独自創薬プラットフォームであるPepMetics®は、ペプチドを模倣する独自の骨格をもつ低分子によりタンパク質間相互作用の制御を可能にする技術で、新たな創薬パラダイムを創出する可能性があります。

今回のウェビナーでは、PRISM BioLabの竹原大・代表取締役が、PepMetics®技術の紹介に加え、新たな創薬パラダイムの実現に向けた多くのグローバル製薬企業との連携の状況、パートナーリング、資金調達や組織運営などバイオベンチャー経営の経験談をお話しします。

【概要】
開催日時　：2022年11月9日（水）16:00～17:00
開催形式　：オンライン（Zoom）
言　語 ：日本語
参加費 ：無料
お申し込み：https://lnkd.in/g9iSqZHn

====
Pharma Intelligence Award Japan 2022 Commemorative Webinar "PPI Inhibition by Small Molecules: A New Drug Discovery Paradigm"

PRISM BioLab's proprietary drug discovery platform, PepMetics®, is a technology that enables the control of protein-protein interactions by small molecules with a unique peptide-mimicking backbone, potentially creating a new drug discovery paradigm.

In this webinar, Dai Takehara, President of PRISM BioLab, will introduce the PepMetics® technology and share his experiences in managing a biotech startup, including the status of collaboration with many global pharmaceutical companies, partnering, fundraising and organizational management to realize a new drug discovery paradigm. 

【Outline】
Date & Time ： November 9, 2022 (Wed.) 16:00-17:00 JST
Format ：Online (Zoom)
Language: Japanese
Participation Fee: Free of charge
Registration: https://lnkd.in/g9iSqZHn

PRISM Biolab BLOG Update!

PepMetics®: Our Engine for Paradigm Shifts on PPI Drug Discovery

PRISM is open to all levels of scientific discussion. Our scientists would love to speak with you!

https://lnkd.in/ebv7fDdt

ESMO 2022 is starting tomorrow. Come by our booth 263 to find out how we target undruggable targets with our small molecule peptide mimetics. https://prismbiolab.com
#drugdiscovery #peptides #peptidemimetics #undruggable

Visit PRISM BioLab Co., Ltd. BioLab team at booth 263 at ESMO 2022 conference to find out how we target undruggable targets with our small molecule peptide mimetics. https://prismbiolab.com
#peptides #peptidemimetics #undruggable

Metric
Company Name	PRISM BioLab	大原薬品工業
Symbol
MSH ID	COM:PRISMBIOLAB	JP:CO:OHARA-CH
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	製薬
Country	JP	JP
Stage
Employee Count	6	30
Website	prismbiolab.com	ohara-ch.co.jp
LinkedIn		%E5%A4%A7%E5%8E%9F%E8%96%AC%E5%93%81%E5%B7%A5%E6%A5%AD%EF%BC%88%E6%A0%AA%EF%BC%89
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	5.08K
Web Traffic Growth	-0.82
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:PRISMBIOLAB

PRISM BioLab

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue